SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Woo P.Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome.Nat Clin Pract Rheumatol2006;2:2834.
  • 2
    Prakken B, Albani S, Martini A.Juvenile idiopathic arthritis.Lancet2011;377:213849.
  • 3
    Frosch M, Roth J.New insights in systemic juvenile idiopathic arthritis: from pathophysiology to treatment.Rheumatology (Oxford)2008;47:1215.
  • 4
    Ramanan AV, Grom AA.Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?Rheumatology (Oxford)2005;44:13503.
  • 5
    Vastert SJ, Kuis W, Grom AA.Systemic JIA: new developments in the understanding of the pathophysiology and therapy.Best Pract Res Clin Rheumatol2009;23:65564.
  • 6
    Grom AA.Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? [review].Arthritis Rheum2004;50:68998.
  • 7
    Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J.Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.J Exp Med2005;201:147986.
  • 8
    De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al.Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.N Engl J Med2012;367:238595.
  • 9
    Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al.The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.Arthritis Rheum2008;58:150515.
  • 10
    Martini A.Systemic juvenile idiopathic arthritis.Autoimmun Rev2012;12:569.
  • 11
    Mellins ED, Macaubas C, Grom AA.Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.Nat Rev Rheumatol2011;7:41626.
  • 12
    Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al.Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.N Engl J Med2012;367:2396406.
  • 13
    De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A.Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis.Arthritis Rheum1991;34:115863.
  • 14
    De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A.Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.J Clin Invest1994;93:21149.
  • 15
    De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ.Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.Ann Rheum Dis2007;66:58998.
  • 16
    Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al.Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis.Arthritis Rheum2003;48:26226.
  • 17
    Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, et al.The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis.Arthritis Rheum2009;60:88391.
  • 18
    Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W.Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation.Rheumatology (Oxford)2003;42:3759.
  • 19
    Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al.Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome.Arthritis Res Ther2005;7:R307.
  • 20
    Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A.Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome.J Pediatr2003;142:2926.
  • 21
    De Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, et al.Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.Arthritis Rheum2009;60:278293.
  • 22
    Grom AA, Passo M.Macrophage activation syndrome in systemic juvenile rheumatoid arthritis.J Pediatr1996;129:6302.
  • 23
    Ravelli A.Macrophage activation syndrome.Curr Opin Rheumatol2002;14:54852.
  • 24
    Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al.Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.Rheumatology (Oxford)2010;49:4419.
  • 25
    Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al.Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms.Arthritis Rheum2008;58:28926.
  • 26
    Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al.The German etanercept registry for treatment of juvenile idiopathic arthritis.Ann Rheum Dis2004;63:163844.
  • 27
    Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al.Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.Rheumatology (Oxford)2012;51:140715.
  • 28
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al.Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.JAMA2011;306:23407.
  • 29
    Otten MH, Prince FH, Anink J, ten Cate R, Hoppenreijs EP, Armbrust W, et al.Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.Ann Rheum Dis2013;72:7217.
  • 30
    Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al, on behalf of the Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pediatrie (SOFREMIP) and the Club Rhumatismes et Inflammation (CRI).Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.Ann Rheum Dis2008;67:3028.
  • 31
    Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al.A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).Ann Rheum Dis2011;70:74754.
  • 32
    Swart JF, Barug D, Mohlmann M, Wulffraat NM.The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.Expert Opin Biol Ther2010;10:174352.
  • 33
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al.Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.Arthritis Rheum2011;63:54555.
  • 34
    Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Arthritis Care Res (Hoboken)2011;63:46582.
  • 35
    Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al.International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.J Rheumatol2004;31:3902.
  • 36
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A.Preliminary definition of improvement in juvenile arthritis.Arthritis Rheum1997;40:12029.
  • 37
    Wallace CA, Ruperto N, Giannini E.Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.J Rheumatol2004;31:22904.
  • 38
    Wallace CA, Ravelli A, Huang B, Giannini EH.Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.J Rheumatol2006;33:78995.
  • 39
    De Jager W, Prakken B, Rijkers GT.Cytokine multiplex immunoassay: methodology and (clinical) applications.Methods Mol Biol2009;514:11933.
  • 40
    Foell D, Roth J.Proinflammatory S100 proteins in arthritis and autoimmune disease [review].Arthritis Rheum2004;50:376271.
  • 41
    Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al, and the Childhood Arthritis and Rheumatology Research Alliance CARRAnet Investigators.Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.Arthritis Care Res (Hoboken)2013;65:74552.
  • 42
    Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al, for the Paediatric Rheumatology International Clinical Trials Organisation.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Arthritis Rheum2012;64:55767.
  • 43
    Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al.The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.Ann Rheum Dis2012;71:97480.
  • 44
    Jelusic M, Lukic IK, Tambic-Bukovac L, Dubravcic K, Malcic I, Rudan I, et al.Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis.Clin Rheumatol2007;26:13324.
  • 45
    Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al.Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.Rheumatology (Oxford)2010;49:164553.
  • 46
    Shimizu M, Nakagishi Y, Yachie A.Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles.Cytokine2013;61:3458.
  • 47
    Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F.Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years.J Rheumatol2000;27:4916.
  • 48
    Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al.Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study.Arthritis Rheum2000;43:24029.